2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

101. Red Cells and Erythropoiesis, Excluding Iron: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Treatment Considerations, Supportive Care, Biological Therapies, Antibody Therapy, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Computer Vision, Deep Learning, Biological Processes, Apoptosis, Pathogenesis, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Quality of Care, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Bone Marrow Failure Syndromes, Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Immunology, Autoimmune Disorders, Autoimmune Hemolytic Anemia, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Neonatal
PAPER

2870 A multicenter real-world study of efficacy and safety of complement inhibitors (Eculizumab or Iptacopan) combined with cyclosporine in Patients with Aplastic anemia-paroxysmal nocturnal hemoglobinuria (AA-PNH) syndrome

Chuan He Sr, ????, Yuemin Gong, PhD2, Shuqian Xu, ph3, Jingnan Sun4, Yanjuan Lin5, Xinmei Yu, Dr6, Puzhou Wang, Dr7, Yawen Zhang, PhD8, Ting MD, PhD Niu, MD, PhD9, Guangsheng He10
1 Department of Hematology,Institute of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China, National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University, Chengdu, China, State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, China
2 Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China, Nanjing, China
3 Department of Hematology, Qilu Hospital of Shandong University, Jinan, Shandong, China, Jinan, China
4 Department of Hematology,1st Hospital of Jilin University,Changchun, Changchun, China
5 Department of Hematology, Fujian Institute of Hematology,Fujian Provincial Key Laboratory on Hematology,Fujian Medical University Union Hospital, Fuzhou, China
6 Department of Hematology,Institute of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China, National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University, Chengdu, China, State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, China
7 Department of Hematology, Qilu Hospital of Shandong University, Jinan, Shandong, China, Jinan, China
8 Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China, Nanjing, China
9 Department of Hematology,Institute of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China, National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University, Chengdu, China, State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, China
10 Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China, Nanjing, China

Background

 

Aplastic anemia (AA) often occurs concurrently with paroxysmal nocturnal hemoglobinuria (PNH), representing a complex bone marrow failure disorder characterized by both immune-mediated hematopoietic hypoplasia and complement-mediated intravascular hemolysis. Controlling hemolysis and improving hematopoiesis must be addressed simultaneously in the treatment. In general, cyclosporine combined with complement inhibitors is recommended. However, data on the safety and efficacy of proximal complement inhibitors combined with cyclosporine in real-world practice remain lacking.

 

Objectives

 

To evaluate the efficacy and safety of complement inhibitors (eculizumab and iptacopan) combined with cyclosporine in Chinese adult patients with concurrent AA and PNH, for reference of subequent clinical use.

 

Methods

 

Enrolled adult patients had a confirmed diagnosis of AA and PNH. Patients received standard-dose eculizumab or iptacopan combined with cyclosporine. The observation period was 24 weeks. Primary endpoints included the proportion of patients with an increase in hemoglobin (Hb) level ≥2 g/dL from baseline, the proportion of patients with Hb normalization (Hb ≥12 g/dL), and safety at Week 24. Secondary endpoints included the proportion of transfusion independence at Week 24, changes from baseline in hemoglobin (Hb) and lactate dehydrogenase (LDH) levels, breakthrough hemolysis, and major adverse vascular events (MAVEs).

 

Results

 

A total of 45 patients were enrolled between January 2024 and January 2026. Baseline characteristics were balanced between the two groups (Table 1). At Week 24, the proportion of patients achieving the primary endpoint (Hb increase≥2g/dL) was 28.6% (6/21)in the eculizumab group and 66.7%(16/24) in the iptacopan group (P=0.014). The proportion of patients with normalized Hb (≥12g/dL) was 14.3% (3/21) and 54.2%(13/24), respectively (P=0.007). The mean Hb increase from baseline was +1.1 g/dL(+19.9%) and +4.3 g/dL(+80.6%) in the two groups (P=0.004); the median Hb increase was +1.2 g/dL and +4.8 g/dL, respectively (P=0.004). The proportion of patients achieving transfusion independence was 46.2%(6/13) and 100%(15/15), respectively (P=0.002) (Table 2). At Week 24, LDH levels were significantly and rapidly controlled in both groups, with mean reductions from baseline of 49.5% and 53.1%, respectively, and mean LDH levels remained below 1.5×ULN in both groups.Baseline FACIT-Fatigue scores were 24.41 and 25.41 for the eculizumab and iptacopan groups, rising to 35.12 and 36.29 at Week 24. Mean fatigue score increments were 10.71 and 10.88 points, indicating visible alleviation of fatigue symptoms in both arms. No treatment-related adverse events of grade ≥3, breakthrough hemolysis or MAVEs were observed.

 

Conclusions

 

This real-world study demonstrates that complement inhibitors (eculizumab and iptacopan) combined with cyclosporine can rapidly and effectively control hemolysis and significantly improve anemia in Chinese patients with AA and PNH. Both regimens are well tolerated. Iptacopan shows a superior trend in increasing hemoglobin and achieving transfusion independence. Further studies with larger sample sizes and longer follow-up are warranted to evaluate long-term efficacy, impact on disease progression, and comprehensive benefits on patient outcomes.

 

Keywords: Paroxysmal nocturnal hemoglobinuria; Aplastic anemia; Iptacopan; Eculizumab

Chuan He Sr, ????: No relevant conflicts of interest to declare.